Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotechnology company, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. The company's Co-Founder and CEO, Dr. Timothy Lu, presented at the event, sharing insights about his journey, dedication to the company, and passion for their development programs.
The presentation, which focuses on Senti's proprietary Gene Circuit platform for next-generation cell and gene therapies, is now available for viewing on virtualinvestorco.com and the company's investor relations website.
Senti Biosciences (NASDAQ:SNTI), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione alla conferenza virtuale per investitori "What's Your Story" Summer Spotlight On-Demand. Il cofondatore e CEO dell'azienda, Dr. Timothy Lu, ha tenuto una presentazione durante l'evento, condividendo la sua esperienza, l'impegno verso l'azienda e la passione per i programmi di sviluppo.
La presentazione, che si concentra sulla piattaforma proprietaria Gene Circuit di Senti per terapie cellulari e geniche di nuova generazione, è ora disponibile per la visione su virtualinvestorco.com e sul sito web per le relazioni con gli investitori dell'azienda.
Senti Biosciences (NASDAQ:SNTI), una empresa biotecnológica en etapa clínica, anunció su participación en la conferencia virtual para inversores "What's Your Story" Summer Spotlight On-Demand. El cofundador y CEO de la compañía, Dr. Timothy Lu, presentó en el evento, compartiendo su trayectoria, dedicación a la empresa y pasión por sus programas de desarrollo.
La presentación, que se centra en la plataforma propietaria Gene Circuit de Senti para terapias celulares y génicas de próxima generación, ya está disponible para su visualización en virtualinvestorco.com y en el sitio web de relaciones con inversores de la empresa.
Senti Biosciences (NASDAQ:SNTI)는 임상 단계의 생명공학 기업으로, 가상 투자자 컨퍼런스 "What's Your Story" Summer Spotlight On-Demand에 참여한다고 발표했습니다. 회사의 공동 창립자이자 CEO인 Dr. Timothy Lu가 행사에서 발표를 진행하며 자신의 여정, 회사에 대한 헌신, 개발 프로그램에 대한 열정을 공유했습니다.
이번 발표는 차세대 세포 및 유전자 치료를 위한 Senti의 독자적인 Gene Circuit 플랫폼에 초점을 맞추고 있으며, 현재 virtualinvestorco.com과 회사의 투자자 관계 웹사이트에서 시청할 수 있습니다.
Senti Biosciences (NASDAQ:SNTI), une société de biotechnologie en phase clinique, a annoncé sa participation à la conférence virtuelle pour investisseurs "What's Your Story" Summer Spotlight On-Demand. Le cofondateur et PDG de l'entreprise, Dr. Timothy Lu, a présenté lors de l'événement, partageant son parcours, son engagement envers la société et sa passion pour leurs programmes de développement.
La présentation, qui met l'accent sur la plateforme propriétaire Gene Circuit de Senti pour les thérapies cellulaires et géniques de nouvelle génération, est désormais disponible en replay sur virtualinvestorco.com ainsi que sur le site des relations investisseurs de la société.
Senti Biosciences (NASDAQ:SNTI), ein biotechnologisches Unternehmen in der klinischen Phase, gab seine Teilnahme an der virtuellen Investorenkonferenz "What's Your Story" Summer Spotlight On-Demand bekannt. Der Mitbegründer und CEO des Unternehmens, Dr. Timothy Lu, präsentierte auf der Veranstaltung und teilte Einblicke in seinen Werdegang, sein Engagement für das Unternehmen und seine Leidenschaft für die Entwicklungsprogramme.
Die Präsentation, die sich auf Sentis firmeneigene Gene Circuit-Plattform für Zell- und Gentherapien der nächsten Generation konzentriert, ist jetzt auf virtualinvestorco.com und der Investor-Relations-Website des Unternehmens verfügbar.
- None.
- None.
– Video webcast now available on-demand
SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website (sentibio.com)
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When did Senti Biosciences (SNTI) participate in the Virtual Investor Summer Spotlight Conference?
Where can investors watch Senti Biosciences' (SNTI) Virtual Investor Conference presentation?
What is Senti Biosciences' (SNTI) main technology platform?
Who presented at the Virtual Investor Conference for Senti Biosciences (SNTI)?
